The aim is to improve patient monitoring both in hospital and at home, allowing treatment to be tailored more closely to the individual patient.
As part of the JTF project 'Improving Patient Care through Advanced Biomonitoring Solutions', UMCG collaborates with projectleader ParaMedir and several regional partners to develop innovative biomonitoring technology.
Researchers from the UMCG Departments of Cardiology, Intensive Care and Smart Implants contribute to the development and clinical validation of the technology. While the primary focus is on heart failure, the platform also has potential applications for other acute or chronic conditions, including kidney disease and diabetes.
Upon successful completion, the project should empower and ease strain on healthcare systems and meet the needs of an aging population by producing innovative biomonitoring devices and software solutions. It aims to deliver advancements in technology, reduce healthcare costs, foster regional innovation, and create high-value job opportunities.
The project may also act as a stepping stone towards implantable biosensors, paving the way for future healthcare solutions.
Maarten W. N. Nijsten,project coordinator UMCG
send a message
Amount: € 1.834.651,14
The project Improving patient care through advanced biomonitoring solutions’ (JTFN – 00055) is ongoing and is financed by the Just Transition Funds (JTF) and co-financed by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Commission. Neither the European Union nor the granting authority can be held responsible for them.
